Leaders in Life Sciences

著者： Dr. Kesha Chauhan MD
無料で聴く

  • サマリー

  • The Leaders in Life Sciences podcast features daily news, strategies, interviews with healthcare professionals, and life science executives. This show is for commercial and medical leaders who want to stay up to date and inspired in their daily work.

    Hosted on Acast. See acast.com/privacy for more information.
    Dr. Kesha Chauhan, MD
    続きを読む 一部表示

あらすじ・解説

The Leaders in Life Sciences podcast features daily news, strategies, interviews with healthcare professionals, and life science executives. This show is for commercial and medical leaders who want to stay up to date and inspired in their daily work.

Hosted on Acast. See acast.com/privacy for more information.
Dr. Kesha Chauhan, MD
続きを読む 一部表示
エピソード
  • #21 : Pfizer's New Obesity Drug

    #21 : Pfizer's New Obesity Drug
    2025/01/13
    Pfizer is heavily investing in its experimental obesity drug, danuglipron, aiming for a once-daily oral pill to compete with the currently dominant injectable weight-loss treatments from Eli Lilly and Novo Nordisk. CEO Albert Bourla expressed cautious optimism, anticipating data from dose-testing studies within months and a potential market entry as the second oral option. While Pfizer is not pursuing acquisitions in the injectable GLP-1 market, they remain open to acquiring other types of obesity treatments. The company's goal is to provide a convenient and competitive alternative in a market projected to reach $150 billion annually by the early 2030s. The unrelated mention of a "Bio Leg" device suggests extraneous information included in the source material.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    4 分
  • #20 : Acquiring Patient Social Networks

    #20 : Acquiring Patient Social Networks
    2025/01/12
    Swoop, an AI-driven healthcare marketing business, acquired MyHealthTeam, a company that runs condition-specific online patient communities1. MyHealthTeam has over 60 communities, some with over 100,000 members, focused on chronic and rare diseases. These communities feature articles, Q&A sections, and patient conversations. Swoop intends to use this acquisition to enable pharmaceutical companies to engage with patients, scale patient reach, and generate first-party data2. Swoop's offerings include marketing to healthcare professionals and consumers, and planning and tracking TV campaigns. The integration of MyHealthTeam into Swoop's business is intended to enhance its marketing capabilities

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    5 分
  • #19 : RSV Vaccines To Include New Warning

    #19 : RSV Vaccines To Include New Warning
    2025/01/12


    The FDA will require GSK and Pfizer to include a warning about the risk of Guillain-Barré syndrome (GBS) on the labels of their RSV vaccines, Arexvy and Abrysvo, respectively. This decision was made after a postmarketing study showed an increased risk of GBS within 42 days of vaccination. The FDA estimates nine cases of GBS per million doses of Abrysvo and seven cases per million doses of Arexvy in adults 65 and older. Although a causal relationship hasn't been established, the FDA notes that the benefits of the vaccines still outweigh the risks. GSK reports that over 9 million people have received Arexvy with an acceptable safety profile.



    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    4 分
activate_buybox_copy_target_t1

Leaders in Life Sciencesに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。